Article information
Abstract
In this case, a new possible strategy for treatment of hepatitis C virus (HCV) relapsing patients is described. The target of anti-HCV therapy is sustained viral response, but strategies for improving sustained viral response in relapsing patients would be useful, and ribavirin is crucial for obtaining viral response. Six weeks of induction therapy with ribavirin were used to improve efficacy of standard combined antiviral therapy in a patient relapsing to standard therapy. In the present case, the patient had undergone a retreatment with the same regimen with the exception of the six-week induction period with ribavirin. Use of induction therapy with ribavirin in this case has allowed for a sustained viral response without prolonging the interferon exposure time in retreatment.
Keywords:
Induction
Re-treatment
Sustained viral response
Hepatitis C virus
Full text is only aviable in PDF
References
[1.]
T. Poynard, M.F. Yuen, V. Ratziu, C.L. Lai.
Viral hepatitis C.
Lancet, 362 (2003), pp. 2095-2100
[2.]
T. Kumada, H. Toyoda, S. Kiriyama, et al.
Long-term follow-up of patients with hepatitis C with a normal alanine aminotransferase.
J Med Virol, 81 (2009), pp. 446-451
[3.]
S. Zeuzem, T. Berg, B. Moeller, et al.
Expert opinion on the treatment of patients with chronic hepatitis C.
J Viral Hepat, 16 (2009), pp. 75-90
[4.]
S. Bruno, T. Stroffolini, M. Colombo, et al.
Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study.
Hepatology, 45 (2007), pp. 579-587
[5.]
Y. Ueno, J.D. Sollano, G.C. Farrell.
Prevention of hepatocellular carcinoma complicating chronic hepatitis C.
J Gastroenterol Hepatol, 24 (2009), pp. 531-536
[6.]
L. Abenavoli, M. Mazza, P.L. Almasio.
The optimal dose of ribavirin for chronic hepatitis C: From literature evidence to clinical practice: The optimal dose of ribavirin for chronic hepatitis C.
Hepat Mon, 11 (2011), pp. 240-246
[7.]
K. Ogawa, S. Hige, M. Nakanishi, et al.
Immunological and mutagenic actions of ribavirin monotherapy preceding combination therapy with interferon for patients with chronic hepatitis C.
Antivir Ther, 14 (2009), pp. 513-522
[8.]
K. Falasca, C. Ucciferri, P. Mancino, V. Gorgoretti, E. Pizzigallo, J. Vecchiet.
Use of epoetin beta during combination therapy of infection with hepatitis c virus with ribavirin improves a sustained viral response.
J Med Virol, 82 (2010), pp. 49-56
[9.]
C. Ucciferri, K. Falasca, P. Mancino, D. De Tullio, E. Pizzigallo, J. Vecchiet.
High dose of erythropoietin in management of interferon/ribavirin induced anemia.
Hepatogastroenterology, 54 (2007), pp. 2181-2183
[10.]
P. Mancino, K. Falasca, C. Ucciferri, E. Pizzigallo, J. Vecchiet.
Use of hematopoietic growth factor in the management of hematological side effects associated to antiviral treatment for HCV hepatitis.
Mediterr J Hematol Infect Dis, 2 (2010), pp. e2010003
[11.]
I.M. Jacobson, R.S. Brown Jr., B. Freilich, et al.
Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial.
Hepatology, 46 (2007), pp. 971-981
[12.]
S. Brillanti, G. Mazzella, E. Roda.
Ribavirin for chronic hepatitis C: and the mystery goes on.
Dig Liver Dis, 43 (2011), pp. 425-430
[13.]
K. Mori, M. Ikeda, Y. Ariumi, H. Dansako, T. Wakita, N. Kato.
Mechanism of action of ribavirin in a novel hepatitis C virus replication cell system.
Virus Res, 157 (2011), pp. 61-70
[14.]
E. Thomas, J.J. Feld, Q. Li, Z. Hu, M.W. Fried, T.J. Liang.
Ribavirin potentiates interferon action by augmenting interferonstimulated gene induction in hepatitis C virus cell culture models.
Hepatology, 53 (2011), pp. 32-41
[15.]
M. Merli, V. Giannelli, F. Gentili, et al.
Ribavirin priming improves the virological response to antiviral treatment in transplanted patients with recurrent hepatitis C: a pilot study.
Antivir Ther, 16 (2011), pp. 879-885
[16.]
J.M. Pawlotsky, H. Dahari, A.U. Neumann, et al.
Antiviral action of ribavirin in chronic hepatitis C.
Gastroenterology, 126 (2004), pp. 703-714
[17.]
F. Zoulim, J. Haem, S.S. Ahmed, et al.
Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients.
J Viral Hepat, 5 (1998), pp. 193-198
[18.]
A. Tamori, K. Kioka, O. Kurai, et al.
Favorable factors for retreatment with pegylated interferon alpha2a plus ribavirin in patients with high viral loads of genotype 1 hepatitis C virus.
Hepatol Res, 41 (2011), pp. 1169-1177
Copyright © 2012. Elsevier Editora Ltda.. All rights reserved
